Hemophilia Treatment Drugs Market
The global hemophilia treatment drugs market was valued at US$ 9,500 Mn in 2017 and is anticipated to reach US$ 15,000 Mn by 2026, expanding at a CAGR of 5% from 2018 to 2026. Increase in R&D investment by key players for developing new drugs for the treatment of hemophilia and rise in demand for long-acting replacement therapies and non-factor therapies are anticipated to fuel the growth of the global market during the forecast period. North America dominated the global market in 2017 owing to the introduction and uptake of new long-acting factors and alternative coagulation promoters and increase in the rate of diagnosis for hemophilia.
The global hemophilia treatment drugs market is driven by government initiatives such as nationwide network of hemophilia treatment centers (HTCs) funded by the Federal Government in the U.S. Many of the HTCs are located at major university medical and research centers. The Federal Government in the U.S. provides funds for more than 100 HTCs. Treatment, education, and support are provided by medical experts at these HTCs. Patients who are provided care and treated at HTCs are less likely to have hospitalization and bleeding complications than those who avail care elsewhere.
The global hemophilia treatment drugs market has been segmented based on product type, disease indication, distribution channel, and region. In terms of product type, the recombinant coagulation factor concentrates segment is projected to account for significant share of the market during the forecast period. New recombinant pipeline agents and gene therapies, such as Fitusiran (phase III trials) and valoctocogene roxaparvovec (phase III candidate), are expected to gain market share during the forecast period. However, some products such as CSL-689 (phase II/III for hemophilia A and hemophilia B) are likely to account for small market share, as these are positioned as on-demand treatments in a market that is increasingly moving toward prophylaxis.
In terms of disease, the global hemophilia treatment drugs market has been classified into hemophilia A, hemophilia B, and others. The hemophilia A segment accounted for major share of the global hemophilia treatment drugs market in 2017. According to the Centers for Disease Control and Prevention (CDC), the exact number of people living with hemophilia globally is not known; however, hemophilia A affects 1 in 5,000 male births. About 400 babies are born with hemophilia A each year. In terms of distribution channel, the global hemophilia treatment drugs market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held major market share in 2017. The segment is likely to account for leading share of the market during the forecast period.
In terms of region, the global hemophilia treatment drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe accounted for major shares of the global hemophilia treatment drugs market in 2017 and the trend is likely to continue from 2018 to 2026. High rate of immigration from tropical regions, increase in health care budgets by governments, and government initiatives to promote hemophilia treatment contributed to the leading shares of these regions. Asia Pacific is projected to be the most attractive market for hemophilia treatment drugs during the forecast period. The market in Asia Pacific is expected to expand at a high CAGR from 2018 to 2026 due to large number of hemophilia patients opting for recombinant coagulation factor concentrates in developing countries such as India and China. The market in Latin America is poised to expand at a moderate growth rate during the forecast period.
Prominent players operating in the global hemophilia treatment drugs market include Pfizer, Inc., CSL Behring, Kedrion, Shire plc, Novo Nordisk A/S, Bayer AG, F. Hoffmann-La Roche Ltd., and Sanofi. Shire plc accounted for the largest market share in 2017. The company’s dominance of the market is due to its broad product portfolio, extensive geographical presence, and aggressive acquisition strategies. Shire plc strengthened its market position by acquiring Baxalta in June 2016. Baxalta is a key player in the rare diseases and other specialized disorders segments.
Novo Nordisk A/S accounted for the second largest share of the global hemophilia treatment drugs market in 2017 due to wide range of hemophilia drugs and robust pipeline. However, F. Hoffmann-La Roche, a new entrant in the hemophilia treatment drugs market, is expected to outperform Novo Nordisk during the forecast period. Pfizer held the third largest share of the hemophilia treatment drugs market in 2017.
Rising Danger of Hemophilia Cases will Bring Profitable Growth for the Hemophilia Treatment Drugs Market
The hemophilia treatment drugs market is expected to gain tremendous growth opportunities on the back of the rising cases of hemophilia across the globe. The growing number of cases related to hemophilia around the world will serve as a prominent growth factor during the assessment period of 2018-2026.
The global hemophilia treatment drugs market has been segmented as follows:
|
Product |
|
|
Disease Indication |
|
|
Distribution Channel |
|
|
Region |
|
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Hemophilia Treatment Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hemophilia Treatment Drugs Market Analysis and Forecast, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Market Outlook
5.1. Regulatory Scenario by Region/globally
5.2. Key Mergers & Acquisitions
5.3. Pipeline Analysis
5.4. Clinical Trial Analysis
5.5. Technological Advancements
6. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016–2026
6.3.1. Plasma derived coagulation factor concentrates
6.3.1.1. Factor VIII
6.3.1.2. Factor IX
6.3.1.3. Others
6.3.2. Recombinant coagulation factor concentrates
6.3.2.1. Factor VIII
6.3.2.2. Factor IX
6.3.2.3. Others
6.3.3. Others
6.4. Global Hemophilia Treatment Drugs Market Attractiveness, by Product Type
7. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Disease Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Hemophilia Treatment Drugs Market Value Forecast by Disease Indication, 2016–2026
7.3.1. Hemophilia A
7.3.2. Hemophilia B
7.3.3. Others
7.4. Global Hemophilia Treatment Drugs Market Attractiveness, by Disease Indication
8. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Global Hemophilia Treatment Drugs Market Attractiveness, by Distribution Channel
9. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Hemophilia Treatment Drugs Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Hemophilia Treatment Drugs Market Attractiveness, by Country/Region
10. North America Hemophilia Treatment Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016–2026
10.2.1. Plasma derived coagulation factor concentrates
10.2.1.1. Factor VIII
10.2.1.2. Factor IX
10.2.1.3. Others
10.2.2. Recombinant coagulation factor concentrates
10.2.2.1. Factor VIII
10.2.2.2. Factor IX
10.2.2.3. Others
10.2.3. Others
10.3. North America Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016–2026
10.3.1. Hemophilia A
10.3.2. Hemophilia B
10.3.3. Others
10.4. North America Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. North America Hemophilia Treatment Drugs Market Value Forecast by Country, 2016–2026
10.5.1. U.S.
10.5.2. Canada
10.6. North America Hemophilia Treatment Drugs Market Attractiveness Analysis
10.6.1. By Product Type
10.6.2. By Disease Indication
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Hemophilia Treatment Drugs Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2. Europe Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016–2026
11.2.1. Plasma derived coagulation factor concentrates
11.2.1.1. Factor VIII
11.2.1.2. Factor IX
11.2.1.3. Others
11.2.2. Recombinant coagulation factor concentrates
11.2.2.1. Factor VIII
11.2.2.2. Factor IX
11.2.2.3. Others
11.2.3. Others
11.3. Europe Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016–2026
11.3.1. Hemophilia A
11.3.2. Hemophilia B
11.3.3. Others
11.4. Europe Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Europe Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Hemophilia Treatment Drugs Market Attractiveness Analysis
11.6.1. By Product Type
11.6.2. By Disease Indication
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Hemophilia Treatment Drugs Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016–2026
12.2.1. Plasma derived coagulation factor concentrates
12.2.1.1. Factor VIII
12.2.1.2. Factor IX
12.2.1.3. Others
12.2.2. Recombinant coagulation factor concentrates
12.2.2.1. Factor VIII
12.2.2.2. Factor IX
12.2.2.3. Others
12.2.3. Others
12.3. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016–2026
12.3.1. Hemophilia A
12.3.2. Hemophilia B
12.3.3. Others
12.4. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis
12.6.1. By Product Type
12.6.2. By Disease Indication
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Hemophilia Treatment Drugs Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2. Latin America Hemophilia Treatment Drugs Market Value Forecast by Product Type, 2016–2026
13.2.1. Plasma derived coagulation factor concentrates
13.2.1.1. Factor VIII
13.2.1.2. Factor IX
13.2.1.3. Others
13.2.2. Recombinant coagulation factor concentrates
13.2.2.1. Factor VIII
13.2.2.2. Factor IX
13.2.2.3. Others
13.3. Latin America Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016–2026
13.3.1. Hemophilia A
13.3.2. Hemophilia B
13.3.3. Others
13.4. Latin America Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Latin America Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis
13.6.1. By Product Type
13.6.2. By Disease Indication
13.6.3. By Distribution Channel
13.6.4. By Country
14. Middle East & Africa Hemophilia Treatment Drugs Market Analysis and Forecast
14.1.Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016–2026
14.2.1. Plasma derived coagulation factor concentrates
14.2.1.1. Factor VIII
14.2.1.2. Factor IX
14.2.1.3. Others
14.2.2. Recombinant coagulation factor concentrates
14.2.2.1. Factor VIII
14.2.2.2. Factor IX
14.2.2.3. Others
14.2.3. Others
14.3. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016–2026
14.3.1. Hemophilia A
14.3.2. Hemophilia B
14.3.3. Others
14.4. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Hemophilia Treatment Drugs Market Attractiveness Analysis
14.6.1. By Product Type
14.6.2. By Disease Indication
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1.Market Player – Competition Matrix (by Tier and Size of companies)
15.2.Market Share Analysis by Company (2017)
15.3. Company Profiles
15.3.1. Biotest AG.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Business Overview
15.3.1.3. Product Portfolio
15.3.1.4. Financial Overview
15.3.1.5. SWOT Analysis
15.3.1.6. Strategic overview
15.3.2. Bayer AG
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Business Overview
15.3.2.3. Product Portfolio
15.3.2.4. Financial Overview
15.3.2.5. SWOT Analysis
15.3.3. CSL Limited
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Business Overview
15.3.3.3. Product Portfolio
15.3.3.4. Financial Overview
15.3.3.5. SWOT Analysis
15.3.3.6. Strategic overview
15.3.4. F. Hoffmann-La Roche Ltd.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Business Overview
15.3.4.3. Product Portfolio
15.3.4.4. Financial Overview
15.3.4.5. SWOT Analysis
15.3.4.6. Strategic overview
15.3.5. Kedrion
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Business Overview
15.3.5.3. Product Portfolio
15.3.5.4. Financial Overview
15.3.5.5. SWOT Analysis
15.3.5.6. Strategic overview
15.3.6. Novo Nordisk A/S
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Business Overview
15.3.6.3. Product Portfolio
15.3.6.4. Financial Overview
15.3.6.5. SWOT Analysis
15.3.6.6. Strategic overview
15.3.7. Octapharma
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Business Overview
15.3.7.3. Product Portfolio
15.3.7.4. Financial Overview
15.3.7.5. SWOT Analysis
15.3.7.6. Strategic overview
15.3.8. Pfizer, Inc
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Business Overview
15.3.8.3. Product Portfolio
15.3.8.4. Financial Overview
15.3.8.5. SWOT Analysis
15.3.8.6. Strategic overview
15.3.9. Sanofi
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Business Overview
15.3.9.3. Product Portfolio
15.3.9.4. Financial Overview
15.3.9.5. SWOT Analysis
15.3.9.6. Strategic overview
15.3.10. Shire Plc.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Business Overview
15.3.10.3. Product Portfolio
15.3.10.4. Financial Overview
15.3.10.5. SWOT Analysis
15.3.10.6. Strategic overview
List of Tables
Table 01 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
Table 02 Global Hemophilia Treatment Drugs Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factor Concentrates, 2016–2026
Table 03 Global Hemophilia Treatment Drugs Market Value (US$ Mn) Forecast, by Plasma derived coagulation factor concentrates, 2016–2026
Table 04 Global Hemophilia Treatment Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 05 Global Hemophilia Treatment Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 06 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 07 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
Table 08 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 09 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 10 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 11 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
Table 12 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 13 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 14 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 15 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
Table 16 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 17 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 18 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 19 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
Table 20 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 21 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 22 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 23 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
Table 24 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 25 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
List of Figures
Figure 01 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Size, by Product Type (US$ Mn), 2017
Figure 02 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Share Analysis by Region, 2017
Figure 03 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Opportunity Map, by Product Type
Figure 04 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Opportunity Map, by Disease Indication
Figure 05 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Opportunity Map, by Distribution Channel
Figure 06 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
Figure 07 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
Figure 08 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Recombinant coagulation factor concentrates, 2016–2026
Figure 09 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Plasma-derived coagulation factor concentrates, 2016–2026
Figure 10 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
Figure 11 Global Bispecific & Next Generation Recombinant Products Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 12 Global Gene Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 13 Global Hemophilia Treatment Drugs Market Value Share, by Distribution Channel, 2017 and 2026
Figure 14 Global Hemophilia Treatment Drugs Market Value Share, by Disease Indication, 2017 and 2026
Figure 15 Global Hemophilia Treatment Drugs Market Attractiveness, by Disease Indication, 2018–2026
Figure 16 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Hemophilia A, 2016–2026
Figure 17 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Hemophilia B, 2016–2026
Figure 18 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
Figure 19 Global Hemophilia Treatment Drugs Market Value Share, by Distribution Channel, 2017 and 2026
Figure 20 Global Hemophilia Treatment Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 21 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016–2026
Figure 22 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2016–2026
Figure 23 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2016–2026
Figure 24 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 25 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country, 2017 and 2026
Figure 26 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country, 2018–2026
Figure 27 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
Figure 28 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
Figure 29 North America Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 30 North America Gene Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 31 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
Figure 32 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018–2026
Figure 33 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
Figure 34 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018–2026
Figure 35 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 36 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 37 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 38 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
Figure 39 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
Figure 40 Europe Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 41 Europe Gene Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 42 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
Figure 43 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018–2026
Figure 44 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
Figure 45 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018–2026
Figure 46 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 47 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 48 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 49 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
Figure 50 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
Figure 51 Asia Pacific Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 52 Asia Pacific Gene Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 53 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
Figure 54 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018–2026
Figure 55 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
Figure 56 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018–2026
Figure 57 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 58 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 59 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 60 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
Figure 61 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
Figure 62 Latin America Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 63 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
Figure 64 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018–2026
Figure 65 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
Figure 66 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018–2026
Figure 67 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 68 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 69 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 70 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
Figure 71 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
Figure 72 Middle East & Africa Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 73 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
Figure 74 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018–2026
Figure 75 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
Figure 76 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018–2026
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes